GYN cancer patients benefit from hospice
GYN cancer patients benefit from hospice
Study shows longer survival
A retrospective review of patients with recurrent or persistent gynecologic cancers shows a longer survival rate for patients who chose hospice care versus those who did not.1
The researchers evaluated 81 patient records between the years of 2002 and 2008 to collect information on demographics, therapy, clinicopathologic data, hospice utilizations, surgical/invasive procedures and survival. Of the 81 patients included in the study, 29 (36%) declined hospice care when it was recommended by their provider, and 52 (64%) enrolled in hospice when their provider recommended it.
Most patients had ovarian cancer (54.3%), were white (61.7%), and had disease recurrence (72%). In a subset of patients with recurrent disease, median overall survival for patients who did not receive hospice care was nine months, versus 17 months for patients who enrolled in hospice. Patients who did not receive hospice care were more likely to have a procedure performed (55%) within four weeks of their death, including the administration of chemotherapy, than hospice patients (31%).
Reference
1. Keyser EA, Reed BG, Lowery WJ, et al. Hospice enrollment for terminally ill patients with gynecologic malignancies: impact on outcomes and interventions. Gynecol Oncol 2010; 118:274-277.
A retrospective review of patients with recurrent or persistent gynecologic cancers shows a longer survival rate for patients who chose hospice care versus those who did not.Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.